DOM-CAL: Clinical and Biochemical Features for the Identification of Dominant Calpainopathies

Sponsor
IRCCS San Camillo, Venezia, Italy (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05956132
Collaborator
IRCCS Fondazione Stella Maris (Other), Istituto Giannina Gaslini (Other), Ospedale Policlinico San Martino (Other), Universita di Verona (Other), Azienda Ospedaliera Universitaria Senese (Other), Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (Other)
50
2
21.1
25
1.2

Study Details

Study Description

Brief Summary

Mutations in the CAPN3 gene cause muscular dystrophies with dysfunction in calpain-3. Calpainopathies are usually inherited in an autosomal recessive manner but in some families they can occur in a dominant inheritance. The significance of heterozygous variants is difficult to interpret in the absence of family history. In this study, the investigators will review the clinical and laboratory information in a cohort of patients identified in the participating centers, with the aim of improving the diagnostic strategy of dominant calpainopathies.

Condition or Disease Intervention/Treatment Phase
  • Other: retrospective study

Detailed Description

The investigators will review clinical and biomarker information in a cohort of 50 patients with heterozygous variants in the CAPN3 gene. Patients are referred by participating centers who will provide anonymised information on the clinical phenotype and laboratory test results. Suitable subjects will be contacted to obtain informed consent. Pseudonymised anamnestic data will be collected from the patient's clinical history and medical records.The aim is to identify a set of multidisciplinary data sufficient to define a diagnostic algorithm for the dominant calpainopathies.

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Retrospective Analysis of Clinical and Biochemical Features for the Identification of Dominant Inheritance of Calpainopathies
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Jun 5, 2025

Outcome Measures

Primary Outcome Measures

  1. Muscle strenght [through study completion, an average of 1 year]

    Evaluation of muscle strength with MRC Scale (score 1-5 from weaker to stronger)

  2. Muscle biopsy [through study completion, an average of 1 year]

    Evaluation of histology and calpain 3 expression (present, reduced, absent)

  3. Creatin Kinase [through study completion, an average of 1 year]

    Amount of creatine kinase in blood in units (U) of enzyme activity per liter (L) of serum

  4. Clinical history [through study completion, an average of 1 year]

    Data collection sheet from clinical records

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical LGMD phenotype, family history with dominant inheritance or sporadic cases, single variant in CAPN3, second variant excluded by MLPA (Multiplex Ligation Probe Amplification) or by analysis of mRNA extracted from muscle.
Exclusion Criteria:
  • No variants in CAPN3, two variants in CAPN3

Contacts and Locations

Locations

Site City State Country Postal Code
1 San Camillo Irccs Venice-Lido VE Italy 30126
2 IRCCS San Camillo Venice-Lido Italy

Sponsors and Collaborators

  • IRCCS San Camillo, Venezia, Italy
  • IRCCS Fondazione Stella Maris
  • Istituto Giannina Gaslini
  • Ospedale Policlinico San Martino
  • Universita di Verona
  • Azienda Ospedaliera Universitaria Senese
  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Investigators

  • Principal Investigator: RITA BARRESI, DR, IRCCS SAN CAMILLO

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
IRCCS San Camillo, Venezia, Italy
ClinicalTrials.gov Identifier:
NCT05956132
Other Study ID Numbers:
  • 2023.08
First Posted:
Jul 21, 2023
Last Update Posted:
Jul 21, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2023